MX2017011280A - Terapia neuro-afectiva regional topica con cannabinoides. - Google Patents
Terapia neuro-afectiva regional topica con cannabinoides.Info
- Publication number
- MX2017011280A MX2017011280A MX2017011280A MX2017011280A MX2017011280A MX 2017011280 A MX2017011280 A MX 2017011280A MX 2017011280 A MX2017011280 A MX 2017011280A MX 2017011280 A MX2017011280 A MX 2017011280A MX 2017011280 A MX2017011280 A MX 2017011280A
- Authority
- MX
- Mexico
- Prior art keywords
- cannabinoid drug
- cannabinoids
- regional neuro
- therapy
- psychoactive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente invención se refiere a medicamento (s) cannabinoide (s) para el uso en el tratamiento de un estado o condición de enfermedad en pacientes humanos y mamíferos no humanos vía terapia tópica de estimulación aferente del tronco encefálico, en donde el (los) medicamento (s) cannabinoide (s) se administra (n) en una cantidad terapéuticamente efectiva para tratar el estado o la condición de enfermedad en la parte posterior de la región del cuello de los pacientes humanos y mamíferos no humanos para proporcionar terapia neuro-afectiva regional a dichos pacientes humanos y mamíferos no humanos. En ciertas modalidades de realización preferidas, los fármacos cannabinoides que comprenden los medicamentos, no son psicoactivos o son sustancialmente no psicoactivos. En ciertas modalidades de realización, los fármacos cannabinoides están incorporados en un vehículo tópico farmacéuticamente aceptable, por ejemplo, en una crema. En ciertas modalidades de realización preferidas, los fármacos cannabinoides comprenden cannabidiol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562126757P | 2015-03-02 | 2015-03-02 | |
US201662299260P | 2016-02-24 | 2016-02-24 | |
PCT/US2016/020446 WO2016141056A1 (en) | 2015-03-02 | 2016-03-02 | Topical regional neuro-affective therapy with cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017011280A true MX2017011280A (es) | 2018-06-27 |
Family
ID=56849015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011280A MX2017011280A (es) | 2015-03-02 | 2016-03-02 | Terapia neuro-afectiva regional topica con cannabinoides. |
Country Status (11)
Country | Link |
---|---|
US (4) | US10716766B2 (es) |
EP (1) | EP3265081A4 (es) |
JP (1) | JP2018507262A (es) |
CN (1) | CN107530318A (es) |
AU (1) | AU2016226267A1 (es) |
BR (1) | BR112017018944A2 (es) |
CA (1) | CA2978605A1 (es) |
HK (2) | HK1244715A1 (es) |
IL (1) | IL254294A0 (es) |
MX (1) | MX2017011280A (es) |
WO (1) | WO2016141056A1 (es) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2549277B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
CN107951869A (zh) * | 2016-10-14 | 2018-04-24 | 汉义生物科技(北京)有限公司 | 含有大麻二酚的药物制剂及其应用 |
CN107952075A (zh) * | 2016-10-14 | 2018-04-24 | 汉义生物科技(北京)有限公司 | 一种含大麻二酚的组合物及其应用 |
CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技(北京)有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 |
CN108079305A (zh) * | 2016-11-23 | 2018-05-29 | 汉义生物科技(北京)有限公司 | 大麻二酚与三环类抗抑郁药的药物组合物及其用途 |
EP3488220A4 (en) * | 2016-11-29 | 2020-03-04 | Axim Biotechnologies, Inc. | CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND NICOTINE |
CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技(北京)有限公司 | 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
GB2557921A (en) * | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
PE20200338A1 (es) * | 2016-12-20 | 2020-02-14 | Tilray Inc | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil |
EP3582768A4 (en) * | 2017-02-15 | 2020-11-18 | Botanix Pharmaceuticals Ltd | CANNABINOID FORMULATIONS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES |
JP2020508992A (ja) * | 2017-02-15 | 2020-03-26 | ボタニクス ファーマシューティカルズ リミテッド | ざ瘡の処置のためのカンナビノイドの製剤 |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
US20210115748A9 (en) * | 2017-03-27 | 2021-04-22 | Patagonia Pharmaceuticals Llc | Topical compositions and methods of treatment |
CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
HUE058102T2 (hu) | 2017-09-28 | 2022-07-28 | Zynerba Pharmaceuticals Inc | Fragilis X szindróma és autizmus kezelése kannabidiollal |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
WO2019135224A1 (en) * | 2018-01-03 | 2019-07-11 | Icdpharma Ltd. | Taste-enhanced cannabinoid submicron emulsion syrup compositions |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
WO2019144190A1 (en) * | 2018-01-24 | 2019-08-01 | Botanix Pharmaceuticals Ltd | Cannabinoid dosing regime for dermatitis and inflammatory skin conditions |
US20210052492A1 (en) * | 2018-01-24 | 2021-02-25 | Botanix Pharmaceuticals Ltd. | Cannabinoid Dosing Regime For Psoriasis |
WO2019144189A1 (en) * | 2018-01-24 | 2019-08-01 | Botanix Pharmaceuticals Ltd | Cannabinoid dosing regime for acne |
BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
CA3095873A1 (en) * | 2018-04-05 | 2019-10-10 | Steven Robert ERBST | Therapeutic elastic bandage for modulating the endocannabinoid system |
US20230110830A1 (en) * | 2018-04-09 | 2023-04-13 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US11129802B2 (en) * | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US10668045B2 (en) * | 2018-07-12 | 2020-06-02 | Bright Green Corporation | Topical massage oil and cream containing CBD, CBN, curcumin and Boswellia resin |
CA3109622A1 (en) * | 2018-08-17 | 2020-02-20 | Kirsten K. SHEPARD | Cannabidiol composition and methods thereof |
US10588979B1 (en) * | 2018-09-17 | 2020-03-17 | Cody D. Freeze | Cannabinoid and terpene-infused topical cream |
EP3723740A4 (en) * | 2018-10-15 | 2020-10-21 | Vardi, Amnon | SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF |
EP3643303A1 (en) * | 2018-10-22 | 2020-04-29 | InnovativeHealth Group SL | Compounds for use in the treatment or prevention of fibrotic diseases; pharmaceutical, cosmetic compositions and uses thereof |
WO2020117288A1 (en) * | 2018-12-07 | 2020-06-11 | Mckinney Jeffrey A | Deuterated agonists and methods of use |
EP3893858A1 (en) | 2018-12-14 | 2021-10-20 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
JP7303969B2 (ja) * | 2019-01-08 | 2023-07-06 | 株式会社ワンインチ | 電子タバコ用液体組成物及びそれを有する電子タバコ |
US20200254271A1 (en) * | 2019-02-13 | 2020-08-13 | Chiscan Holdings, Llc | Devices and methods for application of non-thermal plasma |
CN109718229B (zh) * | 2019-02-15 | 2021-05-28 | 烟台汉麻生物技术有限公司 | 一种抗炎药物组合物及其应用 |
US11752127B2 (en) | 2019-04-01 | 2023-09-12 | Virbac Corporation | Methods and compositions for treatment of anxiety in animals |
KR20230024426A (ko) * | 2019-05-06 | 2023-02-20 | 트랜스포트 오쏘리티, 인크. | 대마 식용품 제조 시스템 및 방법, 및 결과적인 식용 제품 |
WO2020243352A1 (en) * | 2019-05-28 | 2020-12-03 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
US11839593B2 (en) * | 2019-05-28 | 2023-12-12 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US20220233433A1 (en) * | 2019-06-25 | 2022-07-28 | Ab7 Innovation Sasu | Device in the Form of a Cannabinoid-Based Polymer Matrix |
CN114340604A (zh) * | 2019-06-26 | 2022-04-12 | 康宝动物治疗有限公司 | Cbd组合物 |
US10588871B1 (en) | 2019-06-28 | 2020-03-17 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
US20210022993A1 (en) * | 2019-07-22 | 2021-01-28 | Novilla Pharmaceuticals, Inc. | Method of remotely controlling pain |
EP4017477A1 (en) * | 2019-08-21 | 2022-06-29 | Pure Green Pharmaceuticals, Inc. | Medical apparatus with cannabis sativa l. |
EP4031119A4 (en) * | 2019-09-17 | 2023-08-02 | Zynerba Pharmaceuticals, Inc. | TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY |
JP2022550797A (ja) | 2019-10-03 | 2022-12-05 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | リポソームカンナビノイドおよびその使用 |
US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
WO2021070120A1 (en) * | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
AU2020377914A1 (en) * | 2019-11-08 | 2022-06-02 | Vella Bioscience, Inc. | Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders |
MX2022007019A (es) * | 2019-12-09 | 2022-08-15 | Nicoventures Trading Ltd | Producto oral que contiene un canabinoide. |
US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
US20230158091A1 (en) * | 2020-03-19 | 2023-05-25 | New York Medical College | Cannabinoid medical carrier |
CA3178878A1 (en) * | 2020-04-20 | 2021-10-28 | Fotios M. Plakogiannis | Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain |
JP2023537302A (ja) * | 2020-08-03 | 2023-08-31 | エスシーアイ スパーク リミティド | 微小血管の健常性を維持するための方法 |
CA3187582A1 (en) * | 2020-08-17 | 2022-02-24 | Fotios M. Plakogiannis | Pharmaceutical compositions and methods for treating parkinson's disease |
US20220054446A1 (en) * | 2020-08-18 | 2022-02-24 | Yvette Rose Webb | Targeted treatment with a topical cream of cannabinoids, terpenes, and essential oils |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
WO2022159506A1 (en) * | 2021-01-19 | 2022-07-28 | Merit Therapeutics, Inc. | Deuterated cannabidiol compounds |
CA3213953A1 (en) * | 2021-04-08 | 2022-10-13 | Fotios M. Plakogiannis | Pharmaceutical composition and method for treating seizure disorders |
EP4326251A1 (en) * | 2021-04-19 | 2024-02-28 | Symrise AG | Compositions comprising cannabidiol and, optionally, bisabolol |
JP2024515891A (ja) * | 2021-04-30 | 2024-04-10 | プログレッシブ セラピューティクス インコーポレーテッド | 情緒障害の処置のためのケタミン及びカンナビス |
CN116159045B (zh) * | 2021-11-24 | 2024-03-19 | 四川大学华西医院 | 大麻二酚和/或次大麻二酚在制备局部麻醉药药效增强剂中的应用 |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4262003A (en) | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4767619A (en) | 1981-09-14 | 1988-08-30 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Burn wound dressing material |
IT1170387B (it) | 1982-06-07 | 1987-06-03 | Glaxo Group Ltd | Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono |
US4511563A (en) | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
US5364628A (en) | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
GB8419575D0 (en) | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5016652A (en) | 1985-04-25 | 1991-05-21 | The Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
DE3710216A1 (de) | 1987-03-27 | 1988-10-06 | Rentschler Arzneimittel | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
KR0131327B1 (en) | 1987-08-13 | 1998-04-17 | Glaxo Group Ltd | Indole derivatives |
US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4883660A (en) | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
HU219974B (hu) | 1990-06-07 | 2001-10-28 | Astrazeneca Ab, | Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
HUT64326A (en) | 1990-10-15 | 1993-12-28 | Pfizer | Process for production indole derivatives and pharmaceutical preparations containing these compounds |
US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
GB9103770D0 (en) | 1991-02-22 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
US5807571A (en) | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
DE4314976C1 (de) | 1993-05-06 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung |
WO1995005137A1 (en) | 1993-08-16 | 1995-02-23 | Cygnus Therapeutic Systems | Transdermal delivery system using a combination of permeation enhancers |
KR960015375B1 (ko) | 1994-06-08 | 1996-11-11 | 현대전자산업 주식회사 | 강유전체 박막 제조장치 및 그를 사용한 강유전체 박막 제조방법 |
US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
CA2237306C (en) | 1995-11-13 | 2008-10-07 | Pitmy International N.V. | Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs |
US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
US5872145A (en) | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
WO2000025779A1 (en) | 1998-11-02 | 2000-05-11 | Merck & Co., Inc. | Method of treating migraines and pharmaceutical compositions |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6203796B1 (en) | 1999-07-08 | 2001-03-20 | Andreas D. Papaprodromou | Oregano-based therapeutic composition |
SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US20020165207A1 (en) | 2001-05-02 | 2002-11-07 | Richard Rosenbloom | Compositions and methods for the treatment of diabetic neuropathy |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
MXPA03006265A (es) | 2001-01-16 | 2004-06-25 | Purdue Research Foundation | Metodo de tratamiento de disfuncion relacionada con dopamina mediante administracion de un agonista de receptor de dopamina d1 completo, sin generacion de tolerancia. |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20030013753A1 (en) | 2001-06-05 | 2003-01-16 | Ronald Aung-Din | Transdermal migraine therapy |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US20030167556A1 (en) | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
WO2005000086A2 (en) | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
US8263574B2 (en) * | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
EP1809268B1 (en) | 2004-10-01 | 2011-08-03 | Aché Laboratórios Farmacêuticos S.A. | Alpha-humulene for use in the prophylaxis or treatment of inflammatory pain or oedema |
US20090318507A2 (en) | 2006-05-02 | 2009-12-24 | Chris Rundfeldt | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
US8592424B2 (en) * | 2008-06-30 | 2013-11-26 | Afgin Pharma Llc | Topical regional neuro-affective therapy |
AU2009296457A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
CA2760460C (en) * | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
MX2011011445A (es) | 2009-04-29 | 2011-11-18 | Univ Kentucky Res Found | Composiciones que contienen cannabinoides y metodos para su uso. |
CA2772634C (en) * | 2009-08-31 | 2017-11-21 | Alltranz Inc. | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles |
EP2444081B1 (en) * | 2010-10-19 | 2015-04-08 | Parenteral, A.S. | A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol |
WO2012104845A1 (en) | 2011-02-06 | 2012-08-09 | Ben Gurion University Of The Negev Research And Development Authority | Compositions comprising beta-caryophyllene and methods of utilizing the same |
US8808734B2 (en) * | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
US20150051299A1 (en) | 2012-03-19 | 2015-02-19 | Ariel-University Research And Development Company, Ltd. | Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists |
US9345659B2 (en) | 2012-12-11 | 2016-05-24 | Avon Products, Inc. | Use of melicope extracts to improve conditions caused by excess lipids |
WO2014134127A1 (en) * | 2013-02-26 | 2014-09-04 | Northeastern University | Cannabinergic nitrate esters and related analogs |
KR20160094950A (ko) | 2013-10-31 | 2016-08-10 | 풀 스펙트럼 래버러토리즈, 리미티드 | 테르펜 및 칸나비노이드 제제 |
US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
CA2956919C (en) | 2014-07-21 | 2022-07-19 | Glia, Llc | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
CA2979184C (en) * | 2015-03-10 | 2020-09-08 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
-
2016
- 2016-03-02 US US15/058,946 patent/US10716766B2/en active Active
- 2016-03-02 JP JP2017565040A patent/JP2018507262A/ja active Pending
- 2016-03-02 BR BR112017018944A patent/BR112017018944A2/pt not_active IP Right Cessation
- 2016-03-02 EP EP16759411.8A patent/EP3265081A4/en not_active Withdrawn
- 2016-03-02 CN CN201680025420.2A patent/CN107530318A/zh active Pending
- 2016-03-02 AU AU2016226267A patent/AU2016226267A1/en not_active Abandoned
- 2016-03-02 CA CA2978605A patent/CA2978605A1/en not_active Abandoned
- 2016-03-02 US US15/058,859 patent/US20160256410A1/en not_active Abandoned
- 2016-03-02 WO PCT/US2016/020446 patent/WO2016141056A1/en active Application Filing
- 2016-03-02 MX MX2017011280A patent/MX2017011280A/es unknown
-
2017
- 2017-06-02 US US15/612,375 patent/US20170266128A1/en not_active Abandoned
- 2017-09-03 IL IL254294A patent/IL254294A0/en unknown
-
2018
- 2018-04-03 HK HK18104400.6A patent/HK1244715A1/zh unknown
- 2018-06-28 HK HK18108330.2A patent/HK1248564A1/zh unknown
- 2018-07-12 US US16/033,899 patent/US10172809B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20170266128A1 (en) | 2017-09-21 |
AU2016226267A1 (en) | 2017-09-28 |
BR112017018944A2 (pt) | 2018-05-15 |
US20180318237A1 (en) | 2018-11-08 |
HK1244715A1 (zh) | 2018-08-17 |
CA2978605A1 (en) | 2016-09-09 |
US20160256411A1 (en) | 2016-09-08 |
JP2018507262A (ja) | 2018-03-15 |
US20160256410A1 (en) | 2016-09-08 |
CN107530318A (zh) | 2018-01-02 |
IL254294A0 (en) | 2017-10-31 |
HK1248564A1 (zh) | 2018-10-19 |
EP3265081A1 (en) | 2018-01-10 |
WO2016141056A1 (en) | 2016-09-09 |
US10716766B2 (en) | 2020-07-21 |
EP3265081A4 (en) | 2018-11-21 |
US10172809B2 (en) | 2019-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
MX2019001818A (es) | Terapia neuro afectiva regional topica con cariofilenos. | |
EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
BR112015024869A2 (pt) | administração nasal | |
SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
MY193694A (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
MX2021002321A (es) | Nuevos metodos. | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
EA201491427A1 (ru) | Замещенные фенилимидазопиразолы и их применение | |
MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
CY1125361T1 (el) | Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση | |
BR112021025686A2 (pt) | Formulação de doxorrubicina lipossomal, método para produzir uma formulação de doxorrubicina lipossomal e uso de uma formulação de doxorrubicina lipossomal como um medicamento | |
Tian et al. | Phantom limb pain: A review of evidence-based treatment options | |
RU2015154876A (ru) | Способ хирургического лечения диабетического макулярного отека с наличием витреомакулярной тракции | |
UA69674U (ru) | Способ лечения больных на эритематозно-бульозной рожей | |
UA95686U (uk) | Лікарський засіб для терапії захворювань передміхурової залози в формі супозиторія | |
UA113183C2 (xx) | Спосіб лікування адикції | |
UA111798C2 (uk) | Спосіб лікування хворих на рак прямої кишки | |
EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
UA92051U (uk) | Спосіб аутоліпографтінгу в місцевому лікуванні глибоких опіків |